Bit Digital reported a third-quarter revenue of $27.07 million, down 11% from last year and below analyst estimates. The company saw a significant 232% increase in colocation services revenue, driven by WhiteFiber's NC-1 data center, while Bitcoin mining revenue fell sharply. Net income turned positive at $28.5 million, helped by digital asset gains. Bit Digital is shifting focus away from Bitcoin mining toward Ethereum and AI infrastructure, considering share buybacks amid a stock discount to net asset value.
Bit Digital's Q3 revenue report provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 13, 2026 02:02 WIB: out of 50 priced major cryptocurrencies, 6 rose and 43 fell today. Notable movers include UNI (Uniswap) at Rp109.087 with a 1-day change of -8.11% and a typical hold time of 66 days, AAVE (Aave) at Rp2.060.358 with a 1-day change of -7.86% and a typical hold time of 107 days, and ZIL (Zilliqa) at Rp27 with a 1-day change of -5.18% and a typical hold time of 134 days.
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
TDG Gold Corp. has agreed to sell a 51% interest in its Aurora West property to Freeport-McMoRan for C$110 million in cash. Freeport also has an option to increase its ownership to 75% or 100% by funding an additional C$80 million in exploration and ...
Union Station Homeless Services is requesting community help to donate 627 frozen turkeys for its annual Dinner in the Park event, aiming to serve 6,000 Thanksgiving meals. The turkey drive will be held on November 16-17 in Pasadena, California. Dona...
Timeplast, a materials company with over 9,000 customers, has launched a Regulation A+ offering open to the public to license its patented water-soluble plastic technology. This plastic dissolves in water after a programmed period, reducing plastic w...
DelveInsight's 2026 report highlights more than 100 BCMA-targeted therapies in various clinical stages, focusing on multiple myeloma and other diseases. Leading pharma companies like Pfizer, Regeneron, and AstraZeneca are advancing treatments includi...
